S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"The $51 Billion Laser Revolution" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
"The $51 Billion Laser Revolution" (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"The $51 Billion Laser Revolution" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
"The $51 Billion Laser Revolution" (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"The $51 Billion Laser Revolution" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
"The $51 Billion Laser Revolution" (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"The $51 Billion Laser Revolution" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
"The $51 Billion Laser Revolution" (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NYSE:TAK

Takeda Pharmaceutical (TAK) Competitors

$16.21
+0.09 (+0.56%)
(As of 06/9/2023 ET)
Compare
Today's Range
$16.16
$16.28
50-Day Range
$15.84
$17.11
52-Week Range
$12.28
$17.15
Volume
1.64 million shs
Average Volume
1.76 million shs
Market Capitalization
$51.30 billion
P/E Ratio
21.05
Dividend Yield
1.67%
Price Target
$24.67

TAK vs. GSK, GMAB, ZTS, ALNY, HZNP, REGN, BGNE, VRTX, BMRN, and SNY

Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include GSK (GSK), Genmab A/S (GMAB), Zoetis (ZTS), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics Public (HZNP), Regeneron Pharmaceuticals (REGN), BeiGene (BGNE), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Sanofi (SNY). These companies are all part of the "pharmaceutical preparations" industry.

Takeda Pharmaceutical vs.

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

13.2% of GSK shares are owned by institutional investors. Comparatively, 2.1% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, GSK had 22 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 27 mentions for GSK and 5 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 0.58 beat Takeda Pharmaceutical's score of 0.26 indicating that GSK is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
8 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
5 Negative mention(s)
1 Very Negative mention(s)
Positive
Takeda Pharmaceutical
1 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$36.28 billion1.96$18.50 billion$8.284.20
Takeda Pharmaceutical$29.81 billion1.72$2.35 billion$0.7721.05

GSK received 699 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. However, 57.14% of users gave Takeda Pharmaceutical an outperform vote while only 56.79% of users gave GSK an outperform vote.

CompanyUnderperformOutperform
GSKOutperform Votes
799
56.79%
Underperform Votes
608
43.21%
Takeda PharmaceuticalOutperform Votes
100
57.14%
Underperform Votes
75
42.86%

GSK has a net margin of 47.85% compared to Takeda Pharmaceutical's net margin of 7.91%. GSK's return on equity of 43.27% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
GSK 47.85% 43.27% 8.55%
Takeda Pharmaceutical 7.91% 12.73% 5.80%

GSK pays an annual dividend of $1.36 per share and has a dividend yield of 3.9%. Takeda Pharmaceutical pays an annual dividend of $0.27 per share and has a dividend yield of 1.7%. GSK pays out 16.4% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 35.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.

Takeda Pharmaceutical has a consensus price target of $24.67, indicating a potential upside of 52.17%. Given GSK's higher probable upside, equities analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
3 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.09
Takeda Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

GSK beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TAK vs. The Competition

MetricTakeda PharmaceuticalPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$51.01B$6.07B$4.59B$15.03B
Dividend Yield1.68%2.59%2.28%3.86%
P/E Ratio21.058.47119.0520.97
Price / Sales1.72402.763,399.138.33
Price / Cash4.4920.9692.6223.98
Price / Book1.094.844.707.36
Net Income$2.35B$198.54M$117.99M$902.77M
7 Day Performance0.56%0.40%0.87%1.72%
1 Month Performance-4.53%0.21%1.05%3.83%
1 Year Performance21.06%22.46%18.93%-2.56%

Takeda Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GSK
GSK
2.3458 of 5 stars
$34.62
+1.0%
N/A-19.2%$70.88B$36.28B4.1869,400Analyst Revision
GMAB
Genmab A/S
2.4271 of 5 stars
$39.15
0.0%
$39.15
0.0%
+29.3%$25.83B$2.07B35.271,660
ZTS
Zoetis
2.8642 of 5 stars
$170.14
-0.6%
$221.14
+30.0%
-2.0%$78.62B$8.08B38.4113,800
ALNY
Alnylam Pharmaceuticals
2.4317 of 5 stars
$192.96
+0.3%
$247.20
+28.1%
+41.4%$24.03B$1.04B-22.202,002
HZNP
Horizon Therapeutics Public
2.3039 of 5 stars
$99.80
+0.1%
$111.42
+11.6%
+14.0%$22.82B$3.63B62.772,115Analyst Report
Options Volume
REGN
Regeneron Pharmaceuticals
2.5529 of 5 stars
$748.14
-0.3%
$854.13
+14.2%
+29.7%$81.79B$12.37B20.3311,851Analyst Report
BGNE
BeiGene
2.1117 of 5 stars
$226.14
+1.9%
$289.16
+27.9%
+43.4%$21.64B$1.42B-12.179,200Insider Selling
News Coverage
VRTX
Vertex Pharmaceuticals
2.444 of 5 stars
$330.41
-1.2%
$353.87
+7.1%
+28.7%$85.10B$8.93B26.314,800Analyst Report
News Coverage
BMRN
BioMarin Pharmaceutical
2.351 of 5 stars
$92.01
+0.3%
$118.65
+29.0%
+19.2%$17.27B$2.10B242.133,082
SNY
Sanofi
2.4105 of 5 stars
$51.49
+1.3%
$94.50
+83.5%
-1.4%$129.85B$45.31B18.4691,573

Related Companies and Tools

This page (NYSE:TAK) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -